@entity293 ( @entity293 ) remain a worldwide nosocomial infection problem. Geographic variations in pathogen occurrence and susceptibility profiles require monitoring to provide information to guide new ( @entity28442 [ @entity28442 ]) therapeutic options. Two thousand seven hundred-eighty UTI isolates from Europe (n = 783), Latin America (531), and North America (1,466) were tested and compared against 44 agents by reference methods in the SENTRY Antimicrobial Surveillance Program. The top seven pathogens accounted for 90% of all isolates and the rank order for all regions was: @entity526 (1,316; 47%), Enterococcus spp. (351; 13%), @entity4005 spp. (306; 11%), @entity796 (210; 8%), @entity5609 (145; 5%), Enterobacter spp. (97; 4%), and Citrobacter spp. (78; 3%). The pathogen rank order was similar among regions except for the rarer occurrence of Enterococcus spp. (Rank #6, 4%) in Latin America. @entity526 @entity869 resistance was highest in Europe and Latin America (51-55%). @entity869 (37%), @entity2177 or @entity28442 (4%), and @entity206 / @entity207 (23%) resistance remained lowest in North America. @entity6616 susceptibility in @entity526 was still at acceptable levels and ranged from 91 to 96% across regions. The regional @entity2177 -resistant rank order for @entity796 by region was: Latin America (55%) > Europe (41%) > North America (29%). @entity2176 -resistant enterococci (VRE) were only detected in North America (7%). @entity28442 possessed a 34 to 44% wider spectrum compared to @entity2177 against enterococci UTI isolates. Extended spectrum beta-lactamase rates for @entity526 and @entity4005 spp. were 4 and 19%, respectively. These results emphasized the need to assess the often striking differences in pathogen occurrence and resistance rates among the commonly encountered UTI pathogens.

Susceptibility patterns of orally administered antimicrobials among XXXX pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000).

@entity6616 :: ('MESH:D009582', 'Chemical') :: ['Nitrofurantoin'] @entity796 :: ('287', 'Species') :: ['Pseudomonas aeruginosa', 'P. aeruginosa'] @entity2176 :: ('MESH:D014640', 'Chemical') :: ['Vancomycin'] @entity5609 :: ('584', 'Species') :: ['Proteus mirabilis'] @entity2177 :: ('MESH:D002939', 'Chemical') :: ['ciprofloxacin'] @entity28442 :: ('MESH:C419689', 'Chemical') :: ['BMS284756', 'garenoxacin', 'Garenoxacin'] @entity206 :: ('MESH:D014295', 'Chemical') :: ['trimethoprim'] @entity207 :: ('MESH:D013420', 'Chemical') :: ['sulfamethoxazole'] @entity4005 :: ('MESH:D007710', 'Disease') :: ['Klebsiella'] @entity869 :: ('MESH:D000667', 'Chemical') :: ['ampicillin', 'Ampicillin'] @entity293 :: ('MESH:D014552', 'Disease') :: ['Urinary tract infections', 'UTIs'] @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli']
@entity293 :: (MESH:D014552,Disease) :: ['urinary tract infection']
